DRUG DELIVERY TECHNOLOGIES MARKET ANALYSIS

Drug Delivery Technologies Market Size and Trends

Global drug delivery technologies market is estimated to be valued at USD 44.10 Bn in 2024 and is expected to reach USD Bn 102.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

Advancements in drug delivery systems along with the increasing prevalence of chronic diseases are driving the growth of the market. Various technologies such as oral drug delivery, pulmonary drug delivery, transdermal drug delivery, and others have been enhancing drug delivery capabilities. Targeted drug delivery has been gaining increased focus with the help of nanotechnology which is expected to boost the market growth during the forecast period.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights, By Route of Administration - Accessibility fuels oral segment’s dominance

In terms of route of administration, oral segment is expected to contribute the highest share of the market with 35.1% in 2024, owing to its accessibility and convenience. Oral drug delivery provides easy self-administration without the need for healthcare professionals. This reduces treatment costs and improves compliance for patients needing long-term medication. The non-invasive nature of oral delivery also increases patient acceptance and comfort over alternative routes. Oral drugs can be administered discreetly without needles or apparatus.

Insights, By Therapeutic Area - Advancements in treatment options drive oncology segment's leadership

In terms of therapeutic area, oncology segment is expected to contribute the highest share of the market with 23.1% in 2024, owing to rapid advancements in cancer treatment options. There is significant research underway to develop improved targeted drug carriers and combination therapies for oncology. Novel drug delivery systems help combat challenges in achieving required dosage at tumor sites. Liposomes, polymeric, and antibody-drug conjugates effectively enhance drug loading and binding for chemotherapeutics. These facilitate localized or controlled release of anti-cancer payloads to improve efficacy and safety profiles. 

Insights, By End User - Efficiency boosts ambulatory clinics' leadership

In terms of end user, ambulatory surgical clinics segment is expected to contribute the highest share of the market with 23.12% in 2024, owing to efficiency advantages over hospitals. Ambulatory clinics offer day-case surgeries and infusions without overnight hospitalization. This reduces medical costs for lower acuity procedures and infusions. It provides a convenient option to free up hospital bed capacity for serious cases. Ambulatory clinics also have flexible schedules suited to working patients. Their streamlined workflows and dedicated staff deliver targeted care efficiently. 

Regional Insights

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the drug delivery technologies market, with an estimated share of 39.2% in 2024. This can be attributed to the strong presence of leading pharmaceutical and biotech companies, rising healthcare expenditure, and supportive government policies that encourage R&D activities. Some major players like Johnson & Johnson and Pfizer have established their primary research headquarters in the U.S. and contributed to the development of novel delivery systems.

Fastest-Growing Region: Asia Pacific

Asia Pacific region exhibits the fastest growth and is expected to emerge as a lucrative market in the coming years. This can be accredited to the increasing healthcare needs of the large patient population, growing affordability, and government initiatives to strengthen regional core capabilities in producing sophisticated medical technologies. Several global firms like GlaxoSmithKline PLC have also expanded into countries like China and India to tap growth opportunities.

Drug Delivery Technologies Market Outlook for Key Countries

Significant R&D Investments and U.S. FDA Approvals Propel Market Growth in the U.S.

The U.S. drug delivery technologies market is propelled by substantial investments in research and development aimed at enhancing the efficacy and convenience of therapeutic solutions. These efforts are supported by a robust regulatory framework, with the U.S. FDA actively approving innovative drug delivery systems that cater to diverse healthcare needs. For instance, the approval of Zynquista for diabetes management in January 2023 underscores the commitment to advancing treatment options for chronic diseases.

Expanding Healthcare Expenditures and Healthy China 2030 Initiative

China is rapidly expanding its drug delivery technologies market, driven by rising healthcare expenditures and a growing aging population. The government’s Healthy China 2030 initiative aims to improve healthcare access, which is expected to boost the market growth significantly by 20% by 2025.

Advancements in Pharmaceutical Packaging and Delivery Systems Boost Market Growth in Germany

Germany drug delivery technologies market is influenced by advancements in pharmaceutical packaging and delivery systems. In March 2024, Gerresheimer's CEO, Mr. Dietmar Siemssen, anticipated that deals to supply components for weight loss and diabetes drugs would contribute about 4% to the company's annual growth.

Robust Growth in Drug Delivery Technologies Driven by Biotechnology Investments and Innovation in India

India drug delivery technologies market is experiencing robust growth due to increasing investments in biotechnology and pharmaceuticals. The launch of Bharat Biotech's new intranasal vaccine in March 2023 exemplifies innovation in drug delivery methods, catering to the rising demand for effective vaccines.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by Global Drug Delivery Technologies Market Players

• Established Players: Leading pharmaceutical companies prioritize substantial R&D investments to innovate and enhance drug delivery systems. For instance, in 2022, U.S. firms like Apple , Amazon invested approximately US$ 886 billion in R&D, leveraging technologies like artificial intelligence (AI) to expedite product development and reduce time-to-market
• Mid-Level Players: Companies also form technology partnerships to supplement internal capabilities. Partnerships with technology firms and research institutions enhance technological capabilities and market presence. For instance, in January 2024, DelSiTech raised USD 10.58 million to advance its silica-based drug delivery platform, aiming to collaborate with larger entities for broader application.
• Small-Scale Players: Small-scale companies often target specific market segments with unique products. For example, Disruptive Pharma develops drug products using proprietary Mesoporous Magnesium carbonate technology, focusing on targeted drug delivery solutions.

Emerging Startups in the Global Drug Delivery Technologies Market

Innovative Technologies: Startups like Anthropic are developing AI-powered smart contact lenses and ingestible sensors to non-invasively monitor health conditions. Others focus on trackable microchip-based implants for controlled drug release directly into organs.

Market/Impact: Such advanced technologies may transform drug delivery via minimal interventions. AI lenses could help diagnose eye diseases prescriptive without eye drops or injections. Implants ensuring direct drug delivery to diseased tissues could significantly improve treatment outcomes.

Market Contribution: Startups address patient needs overlooked by others. BriaCell Therapeutics focuses exclusively on breast cancer immunotherapy while Nabriva focuses on urgent care antibacterials for common infections. Their dedicated approaches fill critical market gaps.

Key Takeaways from Analyst

• The global drug delivery technologies market is set for steady growth, driven by the rising prevalence of chronic diseases, an aging population, and advancements in biologic drugs. While developed regions like North America and Europe lead adoption, Asia Pacific is poised for the fastest growth due to increasing healthcare spending and patient populations. Oral drug delivery dominates the market, with transdermal and injectable technologies gaining traction for chronic disease management and vaccinations. However, regulatory challenges and intellectual property issues pose barriers. Continuous innovation and product development remain crucial for success in this evolving market.

Market Report Scope

Market Dynamics

Market Driver - Rising prevalence of chronic diseases

The incidence of various chronic diseases has been steadily increasing across the world. Chronic diseases, such as cancer, diabetes, cardiovascular diseases, etc. are increasingly becoming the major causes of mortality and morbidity globally. For instance, according to WHO reports, non-communicable diseases (NCDs) now cause three-quarters of global deaths, with chronic conditions projected to account for 86% of annual deaths by 2050. Rising obesity, air pollution, and the COVID-19 pandemic have stalled health progress, prompting calls for urgent health system investments to address these challenges.

Market Challenge - Risk of needlestick injuries associated with injectable drug delivery

One of the key challenges for the global drug delivery technologies market is the risk of needlestick injuries associated with traditional injectable drug delivery such as syringes and needles. Needlestick injuries pose severe health and safety risks to healthcare professionals as it can potentially expose them to blood-borne pathogens such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). It has been estimated by the World Health Organization (WHO) in November 2023 that around 3 million needlestick injuries occur among healthcare workers globally each year.

Market Opportunity - Growth in biologics and biosimilars driving demand for advanced drug delivery systems

The growing pipeline of biologics and biosimilars offers lucrative opportunities for drug delivery technologies market players. Biologics are usually administered through injectable routes but have limited shelf life and stability issues when stored at room temperature in traditional delivery forms like vials. This necessitates the need for advanced drug delivery systems such as pre-filled syringes, patch pumps, and auto-injectors that provide benefits of safe and convenient long-term storage and administration of biologics.

Market Segmentation

•  Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Parenteral
    • Intramuscular
    • Intravenous
    • Intra-Arterial
    • Subcutaneous
  • Nasal Drug Delivery
  • Ocular Drug Delivery
  • Topical/Transdermal
•  Therapeutic Area Insights (Revenue, USD Bn, 2019 - 2031)
  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Rheumatology
  • Diabetes
  • Others (Infectious Diseases, etc.)
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Ambulatory Surgical Clinics
  • Diagnostic Centers
  • Hospitals
  • Homecare Settings
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Johnson & Johnson Pvt. Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Bayer AG
  • Abbott Laboratories
  • 3M Company
  • Antares Pharma
  • Alkermes PLC
  • Vectura Group PLC
  • Generex Biotechnology Corporation
  • F. Hoffmann-La Roche Ltd.
  • Medtronic PLC